INVESTIGACIÓN EN ONCOLOGÍA DE CABEZA Y CUELLO
IOCC
University of Padua
Padua, ItaliaPublications in collaboration with researchers from University of Padua (19)
2022
-
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
European Journal of Cancer, Vol. 162, pp. 221-236
-
International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System
Journal of Neurological Surgery, Part B: Skull Base, Vol. 84, Núm. 4, pp. 307-319
2017
-
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors
OncoImmunology, Vol. 6, Núm. 4
-
Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells
Frontiers in Immunology, Vol. 8, Núm. FEB
2016
-
A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer
Journal of Controlled Release, Vol. 236, pp. 79-89
-
Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry
Head and Neck, Vol. 38, pp. E673-E679
-
Reverse immunoediting: When immunity is edited by antigen
Immunology Letters, Vol. 175, pp. 16-20
2015
-
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
Oncoscience, Vol. 2, Núm. 4, pp. 373-381
-
Inventory of current EU paediatric vision and hearing screening programmes
Journal of Medical Screening, Vol. 22, Núm. 2, pp. 55-64
2014
-
Functional avidity-driven activation-induced cell death shapes CTL immunodominance
Journal of Immunology, Vol. 193, Núm. 9, pp. 4704-4711
-
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
PLoS ONE, Vol. 9, Núm. 10
-
Peritoneal tumor carcinomatosis: Pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs
PLoS ONE, Vol. 9, Núm. 11
2013
2012
-
Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for epstein-barr-virus-driven disorders
Clinical and Developmental Immunology, Vol. 2012
-
IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas
Clinical Cancer Research, Vol. 18, Núm. 15, pp. 4080-4091
-
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma
Clinical Cancer Research, Vol. 18, Núm. 10, pp. 2828-2837
2011
-
Differential down-modulation of HLA class i and II molecule expression on human tumor cell lines upon in vivo transfer
Cancer Immunology, Immunotherapy, Vol. 60, Núm. 11, pp. 1639-1645
-
Immunotherapy for EBV-associated malignancies
International Journal of Hematology, Vol. 93, Núm. 3, pp. 281-293
2009
-
Clinical predictors for germline mutations in Head and neck paraganglioma patients: cost reduction strategy in Genetic diagnostic process as fail-out
Cancer Research, Vol. 69, Núm. 8, pp. 3650-3656